<DOC>
	<DOCNO>NCT02827266</DOCNO>
	<brief_summary>This study evaluate effect epoetin beta ( NeoRecormon ) correction anemia quality life participant diabetes chronic renal failure receive dialysis .</brief_summary>
	<brief_title>A Study Epoetin Beta ( NeoRecormon ) Anemic Participants With Diabetes Chronic Renal Failure Who Are Not Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Type 1 2 diabetes Chronic renal failure ( stage 2 stage 5 ) define Glomerular Filtration Rate ( GFR ) less ( &lt; ) 90 milliliter per minute per 1.73 square meter ( mL/min/1.73 m^2 ) Anemia relate chronic kidney disease require treatment erythropoiesisstimulating agent ( ESA ) ( 2 value hemoglobin less equal 11 gram per deciliter [ g/dL ] 3 month prior inclusion ) , hemoglobin great 8 g/dL Anemia due nonrenal cause Poorly control hypertension Treatment erythropoiesis stimulate agent ( ESA ) within 3 month prior study Planned dialysis next 3 month organ transplant History cancer except basal cell cancer cervical cancer situ</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>